{"id":"NCT00375973","sponsor":"University of Cincinnati","briefTitle":"Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome","officialTitle":"A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-09","primaryCompletion":"2012-06","completion":"2014-03","firstPosted":"2006-09-13","resultsPosted":"2015-07-27","lastUpdate":"2015-08-21"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Fatigue Syndrome, Chronic"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":["Sugar Pill"]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of duloxetine compared with placebo for reducing fatigue in patients diagnosed with Chronic Fatigue Syndrome (CFS).","primaryOutcome":{"measure":"Change From Baseline in Multidimensional Fatigue Inventory (MFI)--General Fatigue Subscale Score","timeFrame":"Baseline to endpoint at 12 weeks","effectByArm":[{"arm":"Duloxetine","deltaMin":-3.3,"sd":4.2},{"arm":"Placebo","deltaMin":-1.8,"sd":2.8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.23"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["25660434"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":29},"commonTop":["Nausea","Somnolence","headache","Insomnia","Constipation"]}}